Business
IPD) share price up 6% on study results
The Impedimed Limited (ASX: IPD) share price lifted this morning on positive results from a significant cancer screening study. The results show that its bio-impedance spectroscopy (BIS) technology is more effective in screening and detecting subclinical breast cancer. Particularly in high-risk patients.
The Impedimed share price shot up as high as 18.5 cents in early trade today but has since retreated to 17 cents, up 6.25% at the time of writing.
What did the study find?
The medical device company is developing ‘BIS L-Dex’, a device that incorporates its in-house L-Dex technology and BIS to measure and monitor fluid status in breast cancer patients.
The device sends a low-level electrical signal through the body. As…
-
Noosa News17 hours agoAustralian chocolate gains a competitive edge in global cocoa shortage
-
General20 hours agoBudget billions helps cashed-up state lead debt battle
-
General16 hours agoAustralia’s Iran embassy staff leave after US warning
-
General21 hours agoIran-Israel conflict live: Trump says he will decide on US strikes ‘within the next two weeks’